Keywords
Tamoxifen
Metabolic syndrome
Cardiovascular risk
Framingham
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the occurrence of Metabolic Syndrome (MS) and cardiovascular risk (CVR) in women with breast cancer undergoing Adjuvant Endocrine Therapy (AET) with tamoxifen citrate, attended at the outpatient service of a public hospital in Belém, Brazil. Methods: Observational, descriptive study with a qualitative and quantitative approach, conducted from 2022 to 2024 with 110 women. Sociodemographic, clinical, anthropometric, and biochemical data (glucose, lipid profile, C-reactive protein) were collected. MS was determined according to the NCEP-ATP III criteria and CVR by the Framingham Risk Score. Statistical analyses included Chi-square test and Pearson correlation. Results: MS occurred in 49.09% of participants, with low HDL levels (83.64%) and increased waist circumference (75.45%) as the main components. Most participants were overweight or obese (81.81%) and had elevated cardiovascular risk (64.54%). Positive correlations were observed between the number of MS components, triglycerides, waist circumference, and CVR. Conclusion: The high prevalence of metabolic disorders and cardiovascular risk highlights the importance of continuous clinical and multidisciplinary monitoring to prevent cardiometabolic complications during AET.
References
ALOMAR SA, et al. The effect of tamoxifen on the lipid profile in women: a systematic review and meta-analysis of randomized controlled trials. Experimental Gerontology, 2022; 159: 111680.
BALLING M, et al. Elevated LDL triglycerides and atherosclerotic risk. Journal of the American College of Cardiology, 2023; 81(2): 136–152.
BOVOLINI A, et al. Metabolic syndrome pathophysiology and predisposing factors. International Journal of Sports Medicine, 2021; 42(3): 199–214.
BURGER PM, et al. C-reactive protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations. The American Journal of Cardiology, 2023; 197: 13–23.
BUTTROS DAB, et al. High risk for cardiovascular disease in postmenopausal breast cancer survivors. Menopause, 2019; 26(9): 1024–1030.
CONTALDO F, et al. Nutrition transition and cancer. Nutrients. 2020;12(3):795.
CLEEMAN JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). 2001.
DE OLIVEIRA SANTOS M, et al. Estimativa de incidência de câncer no Brasil, 2023–2025. Revista Brasileira de Cancerologia, 2023; 69(1).
DUARTE DAP, et al. Iniquidade social e câncer de mama feminino: análise da mortalidade. Cadernos Saúde Coletiva, 2020; 28(4): 465–476.
FIGUEIREDO ACDS, et al. Prevalência da obesidade em mulheres tratadas de câncer de mama numa UNACOM em Juiz de Fora. Revista Brasileira de Mastologia, 2016; 26(4): 169–174.
FIOCHI RSF, et al. Avaliação de risco cardiovascular e síndrome metabólica em mulheres com câncer de mama em uso de tamoxifeno. Demetra (Rio J.), 2021; e54231.
GRUNDY SM, et al. Definição de síndrome metabólica: relatório da conferência do Instituto Nacional do Coração, Pulmão e Sangue/Associação Americana do Coração sobre questões científicas relacionadas à definição. Circulation, 2004; 109(3): 433–438.
HUSSEIN DS, ABDULJABBAR RF. Effect of tamoxifen treatment on lipid profile in hormone receptor positive breast cancer women in Duhok City: a cross-sectional study. Asian Pacific Journal of Cancer Care, 2025; 10(2): 451–456.
JAMOVI. The jamovi project. Version 2.3.28 [Software]. 2022.
LAGARES EB, et al. Excesso de peso em mulheres com diagnóstico de câncer de mama em hormonioterapia com tamoxifeno. Revista Brasileira de Cancerologia, 2013; 59(2): 201–210.
LIMA MTM, et al. Influência temporal da terapia endócrina com tamoxifeno e quimioterapia no risco nutricional e obesidade em pacientes com câncer de mama. BMC Cancer, 2017; 17(1): 578.
LIPSY RJ. The national cholesterol education program adult treatment panel III guidelines. Journal of Managed Care Pharmacy, 2003; 9(1 Suppl): 2–5.
MANNA S, HOLZ MK. Tamoxifen action in ER-negative breast cancer. Signal Transduction Insights, 2016; 5: STI.S29901.
MICROSOFT. Microsoft Excel. Redmond: Microsoft Corporation, 2019.
NAHAS EAP, et al. Síndrome metabólica em mulheres na pós-menopausa tratadas de câncer de mama. Revista Brasileira de Ginecologia e Obstetrícia, 2012; 34: 555–562.
OLIVEIRA DS, et al. Avaliação do risco cardiovascular segundo os critérios de Framingham em pacientes com diabetes tipo 2. Arquivos Brasileiros de Endocrinologia & Metabologia, 2007; 51: 268–274.
RAMOS MCF. Síndrome metabólico: revisión de la literatura. Medicina & Laboratorio, 2022; 26(1): 47–62.
REZENDE LDA, et al. Síndrome metabólica em mulheres com câncer de mama: revisão de escopo. Health Sciences Journal, 2024; 14: e1535.
ANTUNES DOS SANTOS B, MEDEIROS DE ANDRADE VR. Perfil socioeconômico, farmacoterapia oral para câncer de mama e sua adesão ao tratamento. Cadernos Esp, 2020; 14(1).
SHU L, et al. Association between ultra-processed food consumption and risk of breast cancer: a systematic review and dose-response meta-analysis of observational studies. Frontiers in Nutrition, 2023; 10: 1250361.
SILVA DMD, et al. Determinantes sociais de saúde associados à realização de mamografia segundo a Pesquisa Nacional de Saúde de 2013 e 2019. Ciência & Saúde Coletiva, 2025; 30(1): 1–12.
SILVA D, DE LACERDA AP. Proteína C reativa de alta sensibilidade como biomarcador de risco na doença coronária. Revista Portuguesa de Cardiologia, 2012; 31(11): 733–745.
SILVA MF, et al. Prevalência da síndrome metabólica: uma revisão de literatura. Scientia Generalis, 2021; 2(2): 298–306.
VITOR AD, ALVAREZ TS. Relação entre ocorrência de síndrome metabólica e alimentação inadequada em adultos: uma breve revisão de literatura. Revista Brasileira de Nutrição Clínica, 2014; 29(1): 81–85.
YU AF, et al. Cardiac safety of reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-Oncology, 2025; 7(4): 430–441.